OKUR
OnKure Therapeutics, Inc.
Biotechnology
Market Cap$57M
5Y Perf.-97.1%
Build Your Comparison
Side-by-side financial analysisOKUR
TNGX
Try popular comparisons:
Stock Comparison
OKUR vs TNGX
Revenue, margins, valuation, and 5-year total return — side by side.
TNGX
Tango Therapeutics, Inc.
Biotechnology
Market Cap$3.59B
5Y Perf.+164.7%
OKUR vs TNGX — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot |  OKUR |  TNGX |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $57M | $3.59B |
| Revenue (TTM) | $0.00 | $57M |
| Net Income (TTM) | $-44M | $-107M |
| Gross Margin | — | 97.3% |
| Operating Margin | — | -206.2% |
| Total Debt | $549K | $34M |
| Cash & Equiv. | $59M | $112M |
OKUR vs TNGX — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
OKUR
TNGX
| Stock | Apr 21 | Jun 26 | Return |
|---|---|---|---|
| OnKure Therapeutics… (OKUR) | 100 | 2.9 | -97.1% |
| Tango Therapeutics,… (TNGX) | 100 | 264.7 | +164.7% |
Price return only. Dividends and distributions are not included.
Quick Verdict: OKUR vs TNGX
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: TNGX leads in 3 of 6 categories, making it the strongest pick for capital preservation and lower volatility and recent price momentum and sentiment. OnKure Therapeutics, Inc. is the stronger pick specifically for growth and revenue expansion and profitability and margin quality. As sector peers, any of these can serve as alternatives in the same allocation.
🥇TNGX emerged as the overall leader. Track its performance:
OKUR
OnKure Therapeutics, Inc.
The Growth Leader
OKUR is the clearest fit if your priority is growth and quality.
- 84.4% revenue growth vs TNGX's 48.3%
- 5.5% margin vs TNGX's -188.2%
Best for: growth and quality
TNGX
Tango Therapeutics, Inc.
The Income Pick
TNGX carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 1.31
- Rev growth 48.3%, EPS growth 26.9%, 3Y rev CAGR 35.9%
- 202.4% 10Y total return vs OKUR's -97.2%
Best for: income & stability and growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth |  OKUR | 84.4% revenue growth vs TNGX's 48.3% |
| Quality / Margins | OKUR | 5.5% margin vs TNGX's -188.2% |
| Stability / Safety |  TNGX | Beta 1.31 vs OKUR's 1.34 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | TNGX | +5.1% vs OKUR's +47.4% |
| Efficiency (ROA) | TNGX | -33.4% ROA vs OKUR's -41.5% |
OKUR vs TNGX — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2025
OKUR vs TNGX — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLTNGXLAGGINGOKUR
OKUROnKure Therapeutics, …
0leads
TNGXTango Therapeutics, I…
4leads
6 Total Categories
CATEGORYLEADERvs OKURMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
TNGX1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
TNGX5/7
Total Returns1Y, 3Y, 5Y total returns with dividends
TNGX6/6
Risk & VolatilityBeta, volatility, and downside exposure
TNGX2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
TNGX leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
TNGX and OKUR operate at a comparable scale, with $57M and $0 in trailing revenue.
| Metric | OKUROnKure Therapeuti… | TNGXTango Therapeutic… |
|---|---|---|
| RevenueTrailing 12 months | $0 | $57M |
| EBITDAEarnings before interest/tax | -$61M | -$115M |
| Net IncomeAfter-tax profit | -$44M | -$107M |
| Free Cash FlowCash after capex | -$51M | -$143M |
| Gross MarginGross profit ÷ Revenue | — | +97.3% |
| Operating MarginEBIT ÷ Revenue | — | -2.1% |
| Net MarginNet income ÷ Revenue | — | -188.2% |
| FCF MarginFCF ÷ Revenue | — | -2.5% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | -100.0% |
| EPS Growth (YoY)Latest quarter vs prior year | +6.7% | +11.1% |
TNGX leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — OKUR and TNGX each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | OKUROnKure Therapeuti… | TNGXTango Therapeutic… |
|---|---|---|
| Market CapShares × price | $57M | $3.6B |
| Enterprise ValueMkt cap + debt − cash | -$1M | $3.5B |
| Trailing P/EPrice ÷ TTM EPS | -0.95x | -35.56x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 57.62x |
| Price / BookPrice ÷ Book value/share | 1.01x | 10.38x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — OKUR and TNGX each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
TNGX leads this category, winning 5 of 7 comparable metrics.
Profitability & Efficiency
TNGX delivers a -41.5% return on equity — every $100 of shareholder capital generates $-42 in annual profit, vs $-45 for OKUR. OKUR carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to TNGX's 0.10x. On the Piotroski fundamental quality scale (0–9), TNGX scores 4/9 vs OKUR's 3/9, reflecting mixed financial health.
| Metric | OKUROnKure Therapeuti… | TNGXTango Therapeutic… |
|---|---|---|
| ROE (TTM)Return on equity | -45.3% | -41.5% |
| ROA (TTM)Return on assets | -41.5% | -33.4% |
| ROICReturn on invested capital | — | -38.5% |
| ROCEReturn on capital employed | -78.4% | -34.0% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 4 |
| Debt / EquityFinancial leverage | 0.01x | 0.10x |
| Net DebtTotal debt minus cash | -$59M | -$79M |
| Cash & Equiv.Liquid assets | $59M | $112M |
| Total DebtShort + long-term debt | $549,000 | $34M |
| Interest CoverageEBIT ÷ Interest expense | -5448.00x | — |
TNGX leads this category, winning 5 of 7 comparable metrics.
Total Returns (Dividends Reinvested)
TNGX leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in TNGX five years ago would be worth $28,256 today (with dividends reinvested), compared to $359 for OKUR. Over the past 12 months, TNGX leads with a +512.7% total return vs OKUR's +47.4%. The 3-year compound annual growth rate (CAGR) favors TNGX at 106.2% vs OKUR's -63.7% — a key indicator of consistent wealth creation.
| Metric | OKUROnKure Therapeuti… | TNGXTango Therapeutic… |
|---|---|---|
| YTD ReturnYear-to-date | +41.9% | +246.5% |
| 1-Year ReturnPast 12 months | +47.4% | +512.7% |
| 3-Year ReturnCumulative with dividends | -95.2% | +776.5% |
| 5-Year ReturnCumulative with dividends | -96.4% | +182.6% |
| 10-Year ReturnCumulative with dividends | -97.2% | +202.4% |
| CAGR (3Y)Annualised 3-year return | -63.7% | +106.2% |
TNGX leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
TNGX leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
TNGX is the less volatile stock with a 1.31 beta — it tends to amplify market swings less than OKUR's 1.34 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. TNGX currently trades 94.4% from its 52-week high vs OKUR's 78.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | OKUROnKure Therapeuti… | TNGXTango Therapeutic… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.34x | 1.31x |
| 52-Week HighHighest price in past year | $5.38 | $32.79 |
| 52-Week LowLowest price in past year | $1.91 | $4.40 |
| % of 52W HighCurrent price vs 52-week peak | +78.1% | +94.4% |
| RSI (14)Momentum oscillator 0–100 | 53.8 | 63.7 |
| Avg Volume (50D)Average daily shares traded | 210K | 3.6M |
TNGX leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | OKUROnKure Therapeuti… | TNGXTango Therapeutic… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $42.70 |
| # AnalystsCovering analysts | — | 13 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
TNGX leads in 4 of 6 categories — strongest in Income & Cash Flow and Profitability & Efficiency. 1 category is tied.
Best OverallTango Therapeutics, Inc. (TNGX)Leads 4 of 6 categories
Loading custom metrics...
OKUR vs TNGX: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is OKUR or TNGX a better buy right now?
Analysts rate Tango Therapeutics, Inc.
(TNGX) a "Buy" — based on 13 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — OKUR or TNGX?
Over the past 5 years, Tango Therapeutics, Inc.
(TNGX) delivered a total return of +182. 6%, compared to -96. 4% for OnKure Therapeutics, Inc. (OKUR). Over 10 years, the gap is even starker: TNGX returned +202. 4% versus OKUR's -97. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — OKUR or TNGX?
By beta (market sensitivity over 5 years), Tango Therapeutics, Inc.
(TNGX) is the lower-risk stock at 1. 31β versus OnKure Therapeutics, Inc. 's 1. 34β — meaning OKUR is approximately 2% more volatile than TNGX relative to the S&P 500. On balance sheet safety, OnKure Therapeutics, Inc. (OKUR) carries a lower debt/equity ratio of 1% versus 10% for Tango Therapeutics, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — OKUR or TNGX?
On earnings-per-share growth, the picture is similar: Tango Therapeutics, Inc.
grew EPS 26. 9% year-over-year, compared to -11. 4% for OnKure Therapeutics, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — OKUR or TNGX?
OnKure Therapeutics, Inc.
(OKUR) is the more profitable company, earning 0. 0% net margin versus -162. 9% for Tango Therapeutics, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: OKUR leads at 0. 0% versus -178. 4% for TNGX. At the gross margin level — before operating expenses — TNGX leads at 96. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — OKUR or TNGX?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is OKUR or TNGX better for a retirement portfolio?
For long-horizon retirement investors, Tango Therapeutics, Inc.
(TNGX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (+202. 4% 10Y return). Both have compounded well over 10 years (TNGX: +202. 4%, OKUR: -97. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between OKUR and TNGX?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: OKUR is a small-cap quality compounder stock; TNGX is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.